# BrightSpring Health Services, Inc.: overview

BTSG · Nasdaq · CIK 1865782 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/btsg.md) · [Financials](/companies/btsg/financials.md) · [Filings](/companies/btsg/filings.md) · [Insiders](/companies/btsg/insiders.md)

Latest reported revenue: [$4.21bn](/filings/0001865782-26-000012.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001865782-26-000012).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,747 d](/filings/0001193125-26-079454.md) | [2,878](/filings/0001193125-26-199339.md) | [3,148](/filings/0001193125-26-327014.md) | [3,334](/filings/0001865782-26-000012.md) | [3,551 d](/filings/0001193125-26-079454.md) | [3,614](/filings/0001193125-26-199339.md) | [3,873](/filings/0001193125-26-327014.md) | [4,213](/filings/0001865782-26-000012.md) |
| Gross margin | % | [12.3% d](/filings/0001193125-26-079454.md) | [11.8%](/filings/0001193125-26-199339.md) | [11.9%](/filings/0001193125-26-327014.md) | [11.8%](/filings/0001865782-26-000012.md) | [11.6% d](/filings/0001193125-26-079454.md) | [13.3%](/filings/0001193125-26-199339.md) | [12.7%](/filings/0001193125-26-327014.md) | [12.3%](/filings/0001865782-26-000012.md) |
| Operating margin | % | [2.0% d](/filings/0001193125-26-079454.md) | [1.8%](/filings/0001193125-26-199339.md) | [1.5%](/filings/0001193125-26-327014.md) | [2.6%](/filings/0001865782-26-000012.md) | [3.0% d](/filings/0001193125-26-079454.md) | [3.4%](/filings/0001193125-26-199339.md) | [3.4%](/filings/0001193125-26-327014.md) | [3.8%](/filings/0001865782-26-000012.md) |
| Net margin | % | [0.6% d](/filings/0001193125-26-079454.md) | [1.0%](/filings/0001193125-26-199339.md) | [0.9%](/filings/0001193125-26-327014.md) | [1.7%](/filings/0001865782-26-000012.md) | [2.2% d](/filings/0001193125-26-079454.md) | [4.1%](/filings/0001193125-26-199339.md) | [2.2%](/filings/0001193125-26-327014.md) | [2.4%](/filings/0001865782-26-000012.md) |
| Diluted EPS | $ per share | not reported | [0.14](/filings/0001193125-26-199339.md) | [0.13](/filings/0001193125-26-327014.md) | [0.26](/filings/0001865782-26-000012.md) | not reported | [0.67](/filings/0001193125-26-199339.md) | [0.38](/filings/0001193125-26-327014.md) | [0.45](/filings/0001865782-26-000012.md) |
| Free cash flow | $m | [75.3 d](/filings/0001193125-26-079454.md) | [84.0](/filings/0001193125-26-199339.md) | [24.7 d](/filings/0001193125-26-327014.md) | [92.2 d](/filings/0001865782-26-000012.md) | [194 d](/filings/0001193125-26-079454.md) | [101](/filings/0001193125-26-199339.md) | [14.9 d](/filings/0001193125-26-327014.md) | [182 d](/filings/0001865782-26-000012.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $bn | [7.7](/filings/0000950170-25-034196.md) | [7.7](/filings/0001193125-26-079454.md) | [10.1](/filings/0001193125-26-079454.md) | [12.9](/filings/0001193125-26-079454.md) |
| Gross margin | % | [17.5%](/filings/0000950170-25-034196.md) | [14.8%](/filings/0001193125-26-079454.md) | [12.6%](/filings/0001193125-26-079454.md) | [11.8%](/filings/0001193125-26-079454.md) |
| Operating margin | % | [2.4%](/filings/0000950170-25-034196.md) | [0.8%](/filings/0001193125-26-079454.md) | [1.1%](/filings/0001193125-26-079454.md) | [2.3%](/filings/0001193125-26-079454.md) |
| Net margin | % | [(0.7%)](/filings/0000950170-25-034196.md) | [(2.0%)](/filings/0001193125-26-079454.md) | [(0.2%)](/filings/0001193125-26-079454.md) | [1.5%](/filings/0001193125-26-079454.md) |
| Diluted EPS | $ per share | [(0.46)](/filings/0000950170-25-034196.md) | [(1.31)](/filings/0001193125-26-079454.md) | [(0.09)](/filings/0001193125-26-079454.md) | [0.87](/filings/0001193125-26-079454.md) |
| Free cash flow | $bn | [(0.1)](/filings/0000950170-25-034196.md) | [0.1](/filings/0001193125-26-079454.md) | [(0.1)](/filings/0001193125-26-079454.md) | [0.4](/filings/0001193125-26-079454.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/btsg/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-06-05 | [KKR Group Partnership L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 14,669,771 | $58.453 | $857.5m | [Form 4](/filings/0001140361-26-024303.md) |
| 2026-03-04 | [KKR Group Partnership L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 19,715,000 | $40.961 | $807.5m | [Form 4](/filings/0001140361-26-007946.md) |
| 2025-10-22 | [KKR Group Partnership L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 14,745,000 | $28.782 | $424.4m | [Form 4](/filings/0001140361-25-038973.md) |
| 2025-06-24 | [KKR Group Partnership L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 2,100,000 | $21.1519 | $44.4m | [Form 4](/filings/0001140361-25-023831.md) |
| 2025-06-12 | [KKR Group Partnership L.P.](/insiders/1472698.md) | 10% owner | Sale (S) | 13,288,101 | $21.1519 | $281.1m | [Form 4](/filings/0001140361-25-022706.md) |
| 2024-09-11 | [KKR Group Partnership L.P.](/insiders/1472698.md) | 10% owner | Purchase (P) | 11,619,998 | $11.13 | $129.3m | [Form 4](/filings/0001140361-24-041072.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Kohlberg Kravis Roberts & Co. L.P.](/funds/1399770.md) | 2026-06-30 | $1.87bn | 26,829,880 |  | Reduced −14,994,379 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.68bn | 24,027,537 |  | Added +4,425,378 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $934.0m | 13,393,155 |  | Reduced −7,585,378 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $832.8m | 11,942,017 |  | Added +459,861 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $693.7m | 9,946,458 |  | Added +1,913,688 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $510.0m | 7,312,566 |  | Added +1,016,820 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $436.8m | 6,263,316 |  | Added +1,329,375 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $375.9m | 5,183,124 |  | Added +1,618,171 |
| [MANUFACTURERS LIFE INSURANCE COMPANY, THE](/funds/928047.md) | 2026-06-30 | $239.4m | 3,432,423 |  | Reduced −826,842 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $234.4m | 3,360,970 |  | Added +109,579 |

## Recent filings

[All 234 filings](/companies/btsg/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 08:45 ET | [10-Q](/filings/0001865782-26-000012.md) | Quarterly report, period 2026-09-30 | 0001865782-26-000012 |
| 2026-10-30 | 06:05 ET | [8-K](/filings/0001865782-26-000011.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001865782-26-000011 |
| 2026-07-31 | 08:45 ET | [10-Q](/filings/0001193125-26-327014.md) | Quarterly report, period 2026-06-30 | 0001193125-26-327014 |
| 2026-07-31 | 06:05 ET | [8-K](/filings/0001193125-26-326654.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-326654 |
| 2026-06-12 | 16:05 ET | [8-K](/filings/0001193125-26-269360.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-269360 |
| 2026-06-05 | 17:21 ET | [SCHEDULE 13D/A](/filings/0001140361-26-024308.md) | Ownership report, active investor, amended | 0001140361-26-024308 |
| 2026-06-05 | 16:05 ET | [8-K](/filings/0001193125-26-259531.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-259531 |
| 2026-05-21 | 16:15 ET | [8-K](/filings/0001193125-26-234435.md) | 5.07 Shareholder vote results | 0001193125-26-234435 |
| 2026-05-01 | 08:45 ET | [10-Q](/filings/0001193125-26-199339.md) | Quarterly report, period 2026-03-31 | 0001193125-26-199339 |
| 2026-05-01 | 06:05 ET | [8-K](/filings/0001193125-26-198983.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-198983 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-079454.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/20bdce29-2b62-4808-abe8-d943ca5cb5a5)

## About the filer

- CIK: 1865782
- Tickers: BTSG, BTSGU
- Exchange: Nasdaq
- SIC code: 8082 Services-Home Health Care Services
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 31, 2026, 15:25 ET. No prices; not investment advice.